NEW YORK, Aug. 16, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Unicycive and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On June 30, 2025, Unicycive release issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) has issued a CRL [Complete Response Letter] for its New Drug Application (NDA) for OLC to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis."  The press release stated that "[a]fter submitting the NDA, and as a part of the application review and routine information requests, the FDA notified Unicycive that a third-party manufacturing vendor of its main contract development and manufacturing organization (CDMO) was cited for deficiencies following a cGMP inspection."

More on S For Story

• Hundreds Attend Annual Purple Heart Day Banquet Hosted by the Citizens Commission on Human Rights at the Historic Fort Harrison
• 3,000+ Business Owners Create Tasks in One Click and Plan Their Day in Seconds: Voiset App Gets Major Speed Upgrade
• $100 Million Raise Initiative Launched via Share Offering at $4 Level for Cryptocurrency and Real Estate Development Project Company: OFA Group $OFAL
• Author Lorilyn Roberts Explores Humanity's Origins in New YA Sci-Fi Thriller, The Eighth Dimension: Frequency
• The Lady In The Red Dress by Mackay Barr Explores The Dark World Of Human Trafficking

On this news, Unicycive's stock price fell $2.03 per share, or 29.85%, to close at $4.77 per share on June 30, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

---

Show All News | Report Violation